Provided by Tiger Trade Technology Pte. Ltd.

Moderna, Inc.

49.56
-4.0100-7.49%
Post-market: 49.23-0.3300-0.67%19:59 EDT
Volume:7.10M
Turnover:360.62M
Market Cap:19.57B
PE:-6.83
High:53.56
Open:53.29
Low:49.48
Close:53.57
52wk High:59.55
52wk Low:22.28
Shares:394.94M
Float Shares:363.29M
Volume Ratio:1.03
T/O Rate:1.95%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-7.2600
EPS(LYR):-7.2600
ROE:-28.87%
ROA:-14.51%
PB:2.26
PE(LYR):-6.83

Loading ...

Moderna Shares Gain After New Flu Vaccine Clears Regulatory Hurdle

Dow Jones
·
Feb 18

Moderna Says FDA Will Review Flu Shot Submission -- Market Talk

Dow Jones
·
Feb 18

Moderna jumps 5% to $46.11 after FDA reverses course on flu vaccine

TIPRANKS
·
Feb 18

Moderna Shares Extend Gains, Last up 5% Premarket

THOMSON REUTERS
·
Feb 18

Moderna President: Waiting to See a Bit More Stability in Some of the Guidance We're Receiving Around Investment in Vaccines

THOMSON REUTERS
·
Feb 18

Moderna President: We Need Guidance That Will Not Change Year Over Year

THOMSON REUTERS
·
Feb 18

Moderna: We Need Clear Regulatory Rules Applied Consistently

THOMSON REUTERS
·
Feb 18

Moderna President: We Did Agree to Add an Additional Post Marketing Requirement Study

THOMSON REUTERS
·
Feb 18

Stock Track | Moderna Soars 5.28% in Pre-market as FDA Reverses Course, Agrees to Review Flu Vaccine

Stock Track
·
Feb 18

Moderna President Hoge: We Hope Flu Vaccine Will Be Approved in August -Fbn Interview

THOMSON REUTERS
·
Feb 18

US FDA reverses course, will review Moderna's flu vaccine application

Reuters
·
Feb 18

BRIEF-Moderna Announces The U.S. Food And Drug Administration Will Initiate The Review Of Its Investigational Seasonal Influenza Vaccine Submission

Reuters
·
Feb 18

Moderna Shares up 1.53% Premarket After FDA Initiates Review of Co's Influenza Vaccine

THOMSON REUTERS
·
Feb 18

FDA accepts Moderna mRNA-1010 flu vaccine application for review

Reuters
·
Feb 18

Moderna Announces the U.S. Food and Drug Administration Will Initiate the Review of Its Investigational Seasonal Influenza Vaccine Submission

THOMSON REUTERS
·
Feb 18

Moderna: FDA Assigned a Prescription Drug User Fee Act (Pdufa) Goal Date of August 5, 2026

THOMSON REUTERS
·
Feb 18

Moderna: Expects First Potential Approvals for Mrna-1010 in 2026, Subject to Various Ongoing Regulatory Reviews

THOMSON REUTERS
·
Feb 18

Coatue Management: Change in Holdings Are as of Dec 31, 2025 and Compared With the Previous Quarter Ended as of Sept. 30, 2025

THOMSON REUTERS
·
Feb 18

Health Rounds: Moderna combo flu/COVID vaccine succeeds in mid-stage trial

Reuters
·
Feb 18

Bullish flow in Moderna with shares up 0.34%

TIPRANKS
·
Feb 18